A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation

Richard A. Nash, Razelle Kurzrock, John DiPersio, Julie Marie Vose, Charles Linker, Dipnarine Maharaj, Auayporn P. Nademanee, Robert Negrin, Stephen Nimer, Howard Shulman, Mark Ashby, Dennie Jones, Frederick R. Appelbaum, Richard Champlin

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Delayed platelet recovery is a significant complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) was conducted to assess its safety and to obtain preliminary data on its efficacy in patients with persistent severe thrombocytopenia (<20,000/μL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were enrolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4 μg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No significant adverse effects were observed. Ten patients had recovery of platelet counts during the 28-day study period; 3 of these 10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all baseline marrows were compared with samples after rhTPO treatment, there was no difference in marrow megakaryocyte content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts observed in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no correlation between the dose of rhTPO and the recovery of platelet counts. Increases in serum TPO levels were dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, further studies of treatment strategies with rhTPO in patients with delayed platelet recovery are required.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Thrombopoietin
Hematopoietic Stem Cell Transplantation
Blood Platelets
Platelet Count
Megakaryocytes
Bone Marrow
Therapeutics
Thrombocytopenia
Safety
Serum

Keywords

  • Marrow transplantation
  • Megakaryocytes
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation. / Nash, Richard A.; Kurzrock, Razelle; DiPersio, John; Vose, Julie Marie; Linker, Charles; Maharaj, Dipnarine; Nademanee, Auayporn P.; Negrin, Robert; Nimer, Stephen; Shulman, Howard; Ashby, Mark; Jones, Dennie; Appelbaum, Frederick R.; Champlin, Richard.

In: Biology of Blood and Marrow Transplantation, Vol. 6, No. 1, 01.01.2000, p. 25-34.

Research output: Contribution to journalArticle

Nash, RA, Kurzrock, R, DiPersio, J, Vose, JM, Linker, C, Maharaj, D, Nademanee, AP, Negrin, R, Nimer, S, Shulman, H, Ashby, M, Jones, D, Appelbaum, FR & Champlin, R 2000, 'A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 6, no. 1, pp. 25-34. https://doi.org/10.1016/S1083-8791(00)70049-8
Nash, Richard A. ; Kurzrock, Razelle ; DiPersio, John ; Vose, Julie Marie ; Linker, Charles ; Maharaj, Dipnarine ; Nademanee, Auayporn P. ; Negrin, Robert ; Nimer, Stephen ; Shulman, Howard ; Ashby, Mark ; Jones, Dennie ; Appelbaum, Frederick R. ; Champlin, Richard. / A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2000 ; Vol. 6, No. 1. pp. 25-34.
@article{3843e10b824d4b63879c76dc1ab0ead1,
title = "A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation",
abstract = "Delayed platelet recovery is a significant complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) was conducted to assess its safety and to obtain preliminary data on its efficacy in patients with persistent severe thrombocytopenia (<20,000/μL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were enrolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4 μg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No significant adverse effects were observed. Ten patients had recovery of platelet counts during the 28-day study period; 3 of these 10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all baseline marrows were compared with samples after rhTPO treatment, there was no difference in marrow megakaryocyte content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts observed in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no correlation between the dose of rhTPO and the recovery of platelet counts. Increases in serum TPO levels were dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, further studies of treatment strategies with rhTPO in patients with delayed platelet recovery are required.",
keywords = "Marrow transplantation, Megakaryocytes, Thrombocytopenia",
author = "Nash, {Richard A.} and Razelle Kurzrock and John DiPersio and Vose, {Julie Marie} and Charles Linker and Dipnarine Maharaj and Nademanee, {Auayporn P.} and Robert Negrin and Stephen Nimer and Howard Shulman and Mark Ashby and Dennie Jones and Appelbaum, {Frederick R.} and Richard Champlin",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1083-8791(00)70049-8",
language = "English (US)",
volume = "6",
pages = "25--34",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation

AU - Nash, Richard A.

AU - Kurzrock, Razelle

AU - DiPersio, John

AU - Vose, Julie Marie

AU - Linker, Charles

AU - Maharaj, Dipnarine

AU - Nademanee, Auayporn P.

AU - Negrin, Robert

AU - Nimer, Stephen

AU - Shulman, Howard

AU - Ashby, Mark

AU - Jones, Dennie

AU - Appelbaum, Frederick R.

AU - Champlin, Richard

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Delayed platelet recovery is a significant complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) was conducted to assess its safety and to obtain preliminary data on its efficacy in patients with persistent severe thrombocytopenia (<20,000/μL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were enrolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4 μg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No significant adverse effects were observed. Ten patients had recovery of platelet counts during the 28-day study period; 3 of these 10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all baseline marrows were compared with samples after rhTPO treatment, there was no difference in marrow megakaryocyte content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts observed in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no correlation between the dose of rhTPO and the recovery of platelet counts. Increases in serum TPO levels were dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, further studies of treatment strategies with rhTPO in patients with delayed platelet recovery are required.

AB - Delayed platelet recovery is a significant complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) was conducted to assess its safety and to obtain preliminary data on its efficacy in patients with persistent severe thrombocytopenia (<20,000/μL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were enrolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4 μg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No significant adverse effects were observed. Ten patients had recovery of platelet counts during the 28-day study period; 3 of these 10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all baseline marrows were compared with samples after rhTPO treatment, there was no difference in marrow megakaryocyte content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts observed in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no correlation between the dose of rhTPO and the recovery of platelet counts. Increases in serum TPO levels were dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, further studies of treatment strategies with rhTPO in patients with delayed platelet recovery are required.

KW - Marrow transplantation

KW - Megakaryocytes

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0033631018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033631018&partnerID=8YFLogxK

U2 - 10.1016/S1083-8791(00)70049-8

DO - 10.1016/S1083-8791(00)70049-8

M3 - Article

C2 - 10707996

AN - SCOPUS:0033631018

VL - 6

SP - 25

EP - 34

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -